

From a finger prick to fully-automated, on-the-spot diagnostics and real-time disease mapping. **RevDx** is the first portable and affordable handheld device to provide accurate on-the-spot hematologic tests for better treatment decision support. RevDx is for everyone, everywhere.



Addressing an Acute Global Need

The best practice in case of a fever and suspected infection is a **complete blood count (CBC)**. CBC helps physicians manage infections, anaemia and hematologic malignancies. Yet a large portion of the world's population does not have easy access to labs that administer CBC testing. This lack of accessibility leads to vast unnecessary antibiotics prescriptions (**which constitute approx. 50% of total prescriptions**), and can end up encouraging anti-microbial resistance (**AMR**).

The Team

Yoel Ezra, Founder & CEO

30 years of experience in leadership roles. Chief commander of a special technical-operations IDF unit. Recipient of the Prime Minister's Award for unique technological-operation achievement. Director R&D Medical devices. B.A. in Physics, B.Sc. in Electrical Engineering.

Eli Mor, Co-Founder, Venture Partner

30 years of experience across the corporate and technology start-up world, focusing on finance, capital raising, and bizdev in biotech&medtech. A chartered accountant with a B.A. in Finance and Accounting.

Amir Lubashevsky, VP Business Development

36 years of experience in tech company entrepreneurship and bizdev. 30 years of experience in the African market.

Nataly Mizrahi, Ph.D. CTO, Biomedical Engineering

Technion-Israel Institute of Technology
Harvard University, Visiting Scholar

Oran Zohar, Ph.D. Sr. Algorithm & SW Development

Ben-Gurion University,
Austin-Texas, USA, postdoc

Victor Yashunsky, Ph.D. Sr. Algorithm Development

Hebrew University, Physics
Institute Curie, Paris, postdoc

Advisory

Prof. Aaron Ciechanover

Jointly received the **2004 Nobel Prize** for chemistry. Is one of the world's top scientists in the field of Biology, Chemistry, and Medicine

Dr. Ami Neuberger, MD, Medical Advisor

A specialist in internal medicine and infectious diseases. Head of Tropical Diseases & Travel Medicine Center, Rambam Medical Center, Israel. Vast experience working in various low-resource countries. A senior award winning clinical lecturer at the Technion's Faculty of Medicine.

Dr. Josef Rosenblum, MD, Medical Advisor

Chief Medical Informatics Manager at Maccabi Healthcare Services. 35 years of experience in Healthcare IT. Former CIO at Meuhedet Health Services and at Sheba Hospital. Former CTO at Comet. A frequent academic lecturer.

Mr. Josh Shachar, Global Innovation Advisor

Owns 70 patents. A principal owner, founder and CTO of several companies in the field of military aerospace and smart medical devices

Our Vision


To provide healthcare practitioners worldwide with an essential decision-support tool for better treatment in the clinic, during home visits, in emergency situations and throughout remote locations

Our Unique Advantages

- ▶ The most portable Lab-on-Hand.
- ▶ Simple automatic process begins with a finger-prick
- ▶ Rapid results in less than 5 minutes
- ▶ Affordable - less than \$3 per test
- ▶ Multichannel system (microscopy, biosensors, more)
- ▶ Operational anywhere, both offline and online
- ▶ Location-based mapping system and data-analytics
- ▶ Creates an ecosystem for developers for future applications

The Market

EFA's roadmap initially targets the Complete Blood Count (CBC) market, which is estimated to include over 3.6 billion tests in 2019, and the Point of Care (PoC) diagnostic market, which in 2022 is estimated at **~\$38 billion dollars** with an annual **CAGR of 10%**. Our solution is modular, targeting primary care needs and home-hospitalization.



Marketing Strategy & Business Model

EFA will sell its products and services through primary care distribution channels, scaling up to the public sectors and global health sector NGOs. The company will generate revenues from selling proprietary bundles (device and disposable test kits) and data analytics, while also offering more advanced services.

Company Status

Founded: 2016;

Company Stage: post-Seed;

Product stage: Pre-clinical tests and working prototypes

Achievements: An award winning company

Funding :

12/2018 seed Investments: \$1.3M

EHV incubator, Israel Innovation Authority, additional private investors

09/2020 Post seed - \$2.2M

Private & Public investors, Maccabi Fund, Family offices